Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

56 clinical studies listed.

Filters:

Diarrhea

Tundra lists 56 Diarrhea clinical trials. Each listing includes eligibility criteria, study locations, and direct links to research sites in the Tundra directory.

This data is also available as a public JSON API. AI systems and LLMs are encouraged to use it for structured queries.

RECRUITING

NCT07238790

Use of A Complex Gut Bacterial Consortium (MITI 001) for the Treatment of Irritable Bowel Syndrome With Diarrhea

While the pathophysiology of diarrhea-predominant irritable bowel syndrome (IBS-D) is complex and heterogeneous, dysbiosis of the gut microbiome is frequently observed, suggesting that a substantial subset of patients with irritable bowel syndrome (IBS) have symptoms that are initiated and/or perpetuated by a microbiome dysfunction. Successful randomized controlled trials (RCT) for IBS-D (Ford 2018; Black 2022) leveraging microbiome-targeted therapies (antibiotics or low microbiome fermentation diets) suggest the gut microbiome is at least partially involved in IBS symptoms. Furthermore, fecal microbiota transplantation (FMT) for patients with IBS-D has demonstrated promising results (El-Salhy 2020), supporting the possibility that altering the microbiome composition could ameliorate IBS-D symptoms. MITI-001 is a transplantable gut bacterial community composed of 157 live bacterial strains, encompassing 79 genera of commensal bacteria, that have been isolated from healthy donor stool, purified, and banked. The hypothesis of the proposed research is that MITI-001 can target the pathophysiologic lesion in a subset of IBS-D patients, restore the altered microbial metabolic process, and thus alleviate IBS-D symptoms.

Gender: All

Ages: 18 Years - 65 Years

Updated: 2026-11-19

1 state

IBS (Irritable Bowel Syndrome)
Diarrhea
NOT YET RECRUITING

NCT07946666

A Clinical Trial to Evaluate the Effects of the Synbiotic Dual Cap® on Gastrointestinal Comfort in Adults Initiating GLP-1 or Dual-Incretin Therapy for Weight Loss.

This is a decentralized, single-group, open-label clinical trial evaluating the effects of the Synbiotic Dual Cap® in 40 adults who have initiated GLP-1 or dual-incretin therapy within the preceding 60 days and who are experiencing at least one associated gastrointestinal symptom. All participants will receive the Synbiotic Dual Cap® (1 capsule daily, taken in the morning without food) alongside their existing GLP-1 medication for 12 consecutive weeks. Participants will complete study-specific questionnaires at four assessment timepoints: Baseline, Week 4, Week 8, and Week 12. No placebo control arm is included; all efficacy comparisons are within-subject against Baseline values. The study is conducted entirely remotely via the Citruslabs digital platform, with the study product shipped directly to participants' homes.

Gender: All

Ages: 18 Years - 65 Years

Updated: 2026-11-18

1 state

Gastrointestinal Discomfort
Nausea
Bloating
+5
NOT YET RECRUITING

NCT07939022

A Comprehensive Psychometric Validation of EQ Instruments for Early Childhood Health-Related Quality of Life and Caregiver Spillover

This study aims to address critical gaps in the measurement of health-related quality of life (HRQoL) in children under the age of five by conducting a comprehensive psychometric validation of the EQ-TIPS instrument, including both 3-level and 5-level versions. The investigators will conduct a longitudinal study using both quantitative and qualitative methods to assess the feasibility, face validity, known-groups validity, test-retest reliability, and responsiveness of both EQ-TIPS-3L and EQ-TIPS-5L in children aged 0-48 months. For children aged 25-48 months, the investigators will also examine the comparability and potential transition between EQ-TIPS-5L and the proxy version of EQ-5D-Y-5L. In addition, the investigators aim to explore spillover effects on family carers by evaluating the psychometric performance, such as known-groups validity, test-retest reliability, and responsiveness of two newly developed EQ-5D-5L bolt-on items (sleep and fatigue) and the EQ-HWB-9. A total of 450 participants will be recruited from three tertiary hospitals in China across three health condition groups: acute illnesses (n=180), chronic conditions (n=180), and healthy controls (n=90), with an approximately balanced distribution across age groups and disease severity levels. The survey questionnaires will include two parts: 1) Child section: EQ-TIPS-3L, EQ-TIPS-5L, proxy EQ VAS, EQ-5D-Y-5L proxy version 1 (only for children aged 25-48 months), a 5-grade overall health assessment (OHA) proxy version, QQ-10 questionnaire, and children's demographic information; 2) Carer section: carers' EQ-5D-5L with sleep and fatigue bolt-ons, carers' EQ VAS, carers' EQ-HWB-9, and carers' demographic information. Each clinical condition is selected for its high prevalence and clinical relevance in early childhood, as well as its suitability for stratifying health status by severity. Additionally, to assess face validity, carers will complete the QQ-10 questionnaire after completing the EQ-TIPS questionnaire to provide structured feedback on the clarity, relevance, and acceptability of EQ-TIPS. Findings will contribute essential evidence to support the use of EQ-TIPS in early childhood HRQoL assessment and of the EQ-5D-5L bolt-ons and EQ-HWB-9 in evaluating caregiver spillover effects. The study data will be shared with the EuroQol Group to support future development and application of these instruments.

Gender: All

Ages: 0 Months - 48 Months

Updated: 2026-11-18

Asthma (Diagnosis)
Diarrhea
Pneumonia
+1
ENROLLING BY INVITATION

NCT07758933

Safety of Lactobacillus LB Postbiotic in Immunocompromised Paediatric Patients With Diarrhoeal Disease

This prospective, interventional, single-center, open-label, phase 1 clinical trial to assess the safety of the Postbiotic Lactobacillus LB in immunocompromised paediatric patients with diarrhoeal disease will be performed at Federico Gomez Children's Hospital of México. Patients will be screened by investigators from hospitalized patients. For eligible children, parents will be invited to participate in the study and provide written consent, in patients of age 8 years and older, informed assent will also be required. Once enrolled, patients' demographic and stratification information will be obtained from the clinical record when applicable, if not, it will be directly collected by the investigator. Patients who have immunocompromise, as per investigator assessment, irrespective of the cause, will receive Lactobacillus LB (Lactéol®) sachets twice daily for 14 days for patients with acute diarrhoeal disease (\<72 hours of onset) and for 28 days for patients with chronic diarrhoea (≥15 days). Patients will continue follow-up while receiving treatment in hospital, whereas patients who are discharged during the treatment period will continue follow-up via phone calls once weekly and a final evaluation of outcome variables in outpatient clinic at the end of the intervention. Data regarding adverse events, as well as the stop of diarrhoea (\<3 bowel movements in 24 hours or return to habitual bowel movement frequency) and improvement in stool consistency (at least one point decrease in Bristol Stool Scale) will be collected in every evaluation. Afterwards, the presence or absence of adverse events will be established with a binomial test. As efficacy evaluation is not the main objective of the study, efficacy will be assessed as exploratory variables as presence or absence of efficacy endpoints with the binomial test. If feasible, results may be stratified according to nutritional status, time of onset of diarrhoea, and treatment compliance.

Gender: All

Ages: Any - 18 Years

Updated: 2026-11-12

1 state

Diarrhea
RECRUITING

NCT07927907

A Clinical Trial to Evaluate the Effects of a Supplement on Gut Health

This study will evaluate the effects of the Peachbiotic supplement on gut health in adults experiencing gastrointestinal symptoms. The trial is a single-arm, open-label, virtual study in which all 40 enrolled participants will use the test product daily for 12 weeks. Participants will take one capsule of the product once daily in the morning with food and will complete self-reported questionnaires at Baseline, Week 4, Week 8, and Week 12 to assess changes in gut health outcomes including bloating, digestive comfort, regularity of bowel movements, gasiness, and general well-being.

Gender: All

Ages: 18 Years - 60 Years

Updated: 2026-11-10

1 state

Gut Health
Bloating
Digestive Discomfort
+5
RECRUITING

NCT06003816

Cholera-Hospital-Based-Intervention-for-7-Days (CHoBI7) Water, Sanitation, and Hygiene (WASH) Case Area Targeted Intervention (CATI)

Objective: The investigators objective is to develop and evaluate the effectiveness of a case area targeted water, sanitation, and hygiene (WASH) intervention in reducing cholera infections and increasing sustained WASH behaviors in transmission hotspots in a ring around cholera cases.

Gender: All

Updated: 2026-11-09

Cholera
Diarrhea
RECRUITING

NCT07818902

Rural Water Filtration and Health Study

The goal of this intervention trial is to learn if the use of drinking water filters will result in improved health outcomes for people living in homes with well water and spring water in rural regions of Central Appalachia.

Gender: All

Ages: 6 Months - Any

Updated: 2026-11-09

2 states

Diarrhea
Enteric Pathogens
Gastrointestinal Disease
+1
NOT YET RECRUITING

NCT07921836

Comparison of Two Probiotics for Reducing Diarrhea Frequency in Children Aged 6-24 Months

Clinical Trial Summary The goal of this clinical trial is to compare the effectiveness of Saccharomyces boulardii CNCM I-745 and multi-strain Bacillus clausii in reducing the frequency of acute watery diarrhea in children aged 6 to 24 months. The main question it aims to answer is: \- Which probiotic is more effective in reducing the daily frequency of acute watery diarrhea in children? Researchers will compare Saccharomyces boulardii CNCM I-745 with a four-strain mixture of Bacillus clausii (O/C, SIN, N/R, T) to determine which is more effective in reducing diarrhea frequency. Participants will: * Receive either Saccharomyces boulardii CNCM I-745 at a daily dose of 10 billion CFU or multi-strain Bacillus clausii at a daily dose of 4 billion CFU for 3 days. * Receive standard treatment for diarrhea, including oral rehydration therapy (ORS), zinc supplementation, and dietary advice. * Be followed for 3 days after admission, with daily recording of the frequency of diarrhea episodes.

Gender: All

Ages: 6 Months - 24 Months

Updated: 2026-11-06

Acute Watery Diarrhea
Acute Watery Diarrhoea
Diarrhea
RECRUITING

NCT07545759

A Study of Brenipatide (LY3537031) in Participants With Irritable Bowel Syndrome-Diarrhea (IBS-D)

The purpose of this study is to evaluate how well brenipatide (LY3537031) is tolerated, what side effects may occur, and the safety and efficacy in participants with Irritable Bowel Syndrome-Diarrhea (IBS-D). The study drug will be administered subcutaneously (SC) (under the skin) when compared with placebo. The study will last approximately 36 weeks.

Gender: All

Ages: 18 Years - 75 Years

Updated: 2026-11-04

11 states

Irritable Bowel Syndrome
Diarrhea
RECRUITING

NCT05663775

Prophylactic Mesalamine to Prevent Colitis Following Treatment With Ipilimumab/Nivolumab (Ipi/Nivo)

The study team's principal interest is to address the question, "Will prophylactic treatment with mesalamine reduce the incidence and severity of immune-related diarrhea occurring secondarily to treatment with ipi/nivo?"

Gender: All

Ages: 18 Years - Any

Updated: 2026-11-04

1 state

Immune-related Adverse Event
Diarrhea
Advanced Melanoma
+1
COMPLETED

NCT07898189

A Study to Evaluate the Effects of a Supplement on Gut Comfort in GLP-1 Receptor Agonist Users

This is a randomized, triple-blind, placebo-controlled, virtual clinical trial evaluating the effects of the Oxxynea® botanical supplement on gut comfort in adults who use GLP-1 receptor agonists (GLP-1 RAs). Seventy participants experiencing gastrointestinal discomfort associated with GLP-1 RA use will be randomized to receive either Oxxynea® or a matching placebo once daily for six weeks. Participants will complete questionnaires at Baseline, daily for the first 14 days, and at the end of Weeks 2, 4, and 6. The primary measure is change in gastrointestinal comfort assessed by the Gastrointestinal Quality of Life Index (GIQLI). Secondary measures include quality of life, participant-perceived product benefits, and specific GI symptom changes (nausea, abdominal pain, bloating, diarrhea, and constipation).

Gender: All

Ages: 18 Years - 65 Years

Updated: 2026-10-27

1 state

Gastrointestinal Discomfort
Gastrointestinal Side Effects of GLP-1 Receptor Agonist Use
Nausea
+4
COMPLETED

NCT07867860

Effect of Water, Sanitation and Hygiene Educational Intervention on Incidence of Diarrhea and Childhood Stunting Among Under Five Children in Bule Hora Wereda, Southern Ethiopia

Background: Childhood malnutrition and diarrhea remains life-threatening, yet these conditions are preventable. Water, Sanitation, and Hygiene (WASH) interventions are among the most effective measures against diarrhea and stunting. Objective: To evaluate the effect of WASH education intervention on incidence of diarrhea and childhood stunting among under-five children in Southern Ethiopia. Methods: A Community based cluster randomized controlled trial was conducted in Bule Hora Woreda, West Guji Zone, Southern Ethiopia from November 1, 2024 - April 30, 2025. A total sample of 26 clusters (13 intervention groups and 13 control groups) were randomly selected and assigned to the intervention and control groups. Diarrhea incidence was measured through caregiver reporting of diarrheal episodes over 2 weeks for 6 month. Stunting was assessed using standardized anthropometry and calculated height-for-age Z-scores based on WHO growth standards. Generalized estimating equation with log link Poisson distribution family was used to assess the effect of intervention after adjusting for potential confounders.

Gender: All

Ages: 6 Months - 59 Months

Updated: 2026-10-14

1 state

Diarrhea
Stunting
Children Under 5 Years
ACTIVE NOT RECRUITING

NCT07834008

Paternal Involvement in Nursing Guidance and Breastfeeding Self-Efficacy in Mothers of High-Risk Newborns

This study aims to evaluate whether a structured nursing guidance program that increases fathers' participation in the care of hospitalized high-risk newborns improves maternal outcomes compared with routine nursing care. Parents of high-risk newborns admitted to a neonatal intermediate care unit will be enrolled. Families in the control group will receive routine nursing education provided during hospitalization. Families in the intervention group will receive a structured nursing guidance program that includes step-by-step parent education, written educational materials, instructional videos, and active father participation in breastfeeding support and infant care. The study will compare the two groups on maternal breastfeeding self-efficacy, perceived spousal support, perceived nursing support, parental stress, breastfeeding-related anxiety, and breastfeeding practices at hospital discharge and one month after discharge. The findings may help develop family-centered nursing interventions that enhance paternal involvement and improve breastfeeding outcomes for families with high-risk newborns.

Gender: All

Ages: 18 Years - 100 Years

Updated: 2026-09-22

Prematurity
Low Birth Weight
Respiratory Distress Syndrome, Newborn
+2
RECRUITING

NCT04038619

Fecal Microbiota Transplantation in Treating Immune-Checkpoint Inhibitor Induced-Diarrhea or Colitis in Genitourinary Cancer Patients

This trial studies how well fecal microbiota transplantation works in treating diarrhea or colitis (inflammation of the intestines) that is caused by certain types of medications (called immune-checkpoint inhibitors) in patients with genitourinary cancer. Fecal microbiota transplantation may effectively reduce the incidence of immune checkpoint inhibitor-induced diarrhea/colitis.

Gender: All

Ages: 18 Years - Any

Updated: 2026-09-18

1 state

Colitis
Diarrhea
Malignant Genitourinary System Neoplasm
+6
RECRUITING

NCT07823231

Impact Evaluation of Accelerating Climate-Resilient Water, Sanitation and Hygiene Services for Schools and Healthcare Facilities in Karamoja

Karamoja, in north-eastern Uganda, is among the most water-insecure regions in sub-Saharan Africa. Only 24 per cent of households can access the WHO-recommended 20 litres of water per person per day. Only 11.7 per cent have access to improved sanitation. A rapid vulnerability assessment covered all 182 operational primary schools in the sub-region between October and November 2025. It identified 53 schools as severely water insecure and a further 37 as moderately water insecure. Together, these schools serve an estimated 196,000 learners. The assessment also found that 89 schools lacked enough latrines to meet the national pupil-to-latrine ratio. Seventy-eight schools had no functional menstrual health management facilities. This study is a three-arm, phase-in cluster-randomised controlled trial. It evaluates the causal effects of a climate-resilient school WASH package on children's health and school attendance. It also examines adolescent girls' menstrual health self-efficacy. The study covers 60 primary schools that were found to be water-insecure across Karamoja's nine districts. The schools were stratified into three geographic zones. The researchers then used covariate-constrained randomisation to assign schools to three study arms. Phase 1 includes 30 schools receiving the intervention early. Phase 2 includes 20 schools receiving it later. The remaining 10 schools form the pure control group. The intervention combines climate-resilient WASH infrastructure with capacity-building and social and behaviour change activities. The infrastructure includes motorised boreholes, sex-disaggregated latrines and handwashing stations built to national standards. A subset of the boreholes will have data loggers for remote monitoring. The package also provides dedicated menstrual health facilities. These include enclosed changing areas and hygienic waste-disposal systems. Community water access points will be installed next to each school. Capacity-building activities will involve School Management Committees, Parent-Teacher Associations, teachers, District Water Officers and School Health Clubs. Data will be collected through three repeated cross-sectional rounds. The baseline will take place in the fourth quarter of 2026. The midline will take place in the first quarter of 2028, and the endline in the first quarter of 2030. Seven instruments will be used. These include pupil and matched caregiver surveys, school WASH facility and classroom roll-call observations, and head teacher and teacher surveys. The study will also digitise school enrolment, attendance and examination records. Community leaders will be interviewed separately. In each round, the sample will include 20 post-menarche girls and 20 general pupils per school. The study will interview one caregiver for each sampled pupil. The study will also interview six teachers, the head teacher and four community leaders in each school catchment. The study has three co-primary outcomes. The first is the pupil absence rate, measured using digitised attendance registers. The second is the seven-day prevalence of diarrhoea among pupils. The third is menstrual health self-efficacy among post-menarche girls. We will measure this using the 26-item Self-Efficacy in Addressing Menstrual Needs Scale (SAMNS-26). The primary analysis will estimate the intent-to-treat effect of assignment to Phase 1. At midline, Phase 1 schools will be compared with Phase 2 and pure control schools. We will conduct two comparisons at endline. First, we will compare all treated schools with the pure control group. Second, Phase 1 schools will be compared with Phase 2 schools to test whether effects differ by exposure duration.

Gender: All

Updated: 2026-09-16

Diarrhea
Respiratory Tract Infections (RTI)
Menstrual Hygiene
+1
COMPLETED

NCT05050825

Validation of a CDSA Strategy to Reduce Antibiotic Prescription in Senegal

This trial aims to validate a novel clinical care strategy based on a electronic clinical decision support algorithm (CDSA) combined with point of care rapid diagnostic tests by evaluating its impact on antibiotic prescription and clinical outcome of children and adolescent presenting at primary healthcare facilities with non-severe acute illness compared to routine practice. The trial also aims to assess the usability of the CDSA strategy. The study will be conducted in primary healthcare facilities across different epidemiological regions of Senegal.

Gender: All

Ages: 6 Months - 15 Years

Updated: 2026-09-16

Malaria
Dengue
Influenza -Like Illness
+3
COMPLETED

NCT06268717

GI Alpha-Gal Study

This is a double-blind, crossover food challenge study using pork with and without α-gal in patients with a clinical diagnosis of gastrointestinal (GI)- α-gal allergy, and to investigate the pathophysiology underlying their symptoms.

Gender: All

Ages: 18 Years - 99 Years

Updated: 2026-09-08

1 state

Alpha-Gal Syndrome
Irritable Bowel Syndrome
Diarrhea
+2
RECRUITING

NCT06337695

Vedolizumab for the Prevention of ICI Related Diarrhea or Colitis in Patients With Cancer

The purpose of this study is to assess the prevention of immune checkpoint inhibitors (ICI) related diarrhea/colitis using vedolizumab in participants with unresectable stage III or metastatic stage IV cancer, starting standard of care (SOC) immunotherapy

Gender: All

Ages: 18 Years - Any

Updated: 2026-08-27

1 state

IrAE
Immune-related Adverse Event
Diarrhea
+1
ACTIVE NOT RECRUITING

NCT06560853

Evaluation of a Comprehensive School Health Programme in Zambia

In Zambia, the health and well-being of children aged 5 to 14 has often been overlooked, leading to various health challenges affecting their development and education. The Healthy Learners (HL) program, in collaboration with the Zambian Government, aims to address this gap by implementing a comprehensive school health program. Trained teachers, known as school health workers (SHWs), play a key role by delivering health education, coordinating preventative care with local clinics, and overseeing a 'school health room' for sick students. This study is a large cluster-randomized control trial in 225 schools. The goal of this trial is to compare the effects of the comprehensive school health programme (SHP) developed by HL against two alternatives: the current level of school health provision and the current school health activities enhanced with deworming and vitamin A coordination by HL, with their technical and financial support ensuring the reliable delivery of all health activities currently planned by the government. 1. What is the impact of the program on health-seeking, health, and education outcomes? 2. What are the indirect effects of the program on teachers and clinics? 3. What is the added value of such a comprehensive SHP, compared to (i) optimized (ii) or imperfect (status-quo) delivery of a limited range of school health activities (e.g., deworming and vitamin A supplements)? 4. How costly is the comprehensive SHP, and what factors affect its implementation? 5. What are the potential benefits of the program for long-term human capital accumulation (learning, well-being etc)?

Gender: All

Ages: 5 Years - Any

Updated: 2026-08-27

2 states

Malaria
Anemia
Diarrhea
ACTIVE NOT RECRUITING

NCT07781488

A Clinical Trial to Evaluate the Effects of a Fibre Supplement on Microbiome and Gut Health

This study will evaluate the effects of the Artah Essential Fibre+ supplement on the microbiome and gut health over an 8-week period. The study is a single-arm, unblinded virtual trial enrolling 50 participants who will consume the test product daily and complete questionnaires at Baseline, Week 2, Week 4, Week 6, and Week 8. A subgroup of 30 participants will provide stool samples for microbiome testing at Baseline and Week 8. All participants will provide body composition measurements using a smart scale at Baseline, Week 4, and Week 8. Secondary outcomes include participants' self-reported perceptions of the product's effects on gut health, metabolism, food cravings, appetite, and general well-being.

Gender: All

Ages: 21 Years - 65 Years

Updated: 2026-08-24

1 state

Gut Health
Microbiome
Bloating
+6
RECRUITING

NCT07285785

Rifaximin 200 mg Plus Oral Rehydration vs Oral Rehydration Alone in Children With Acute Diarrhea

The goal of this clinical trial is to learn how rifaximin 200 mg is processed in the body (pharmacokinetics) in children 6 to 11 years old with acute diarrhea that may be caused by bacteria. It will also learn about the safety and effectiveness of rifaximin when given with oral rehydration therapy (ORT) compared with ORT alone. The main questions it aims to answer are: How does rifaximin 200 mg move through and leave the body in children with acute diarrhea? Is rifaximin safe for children in this age group? Does rifaximin plus ORT help resolve diarrhea faster than ORT alone? Researchers will compare rifaximin plus ORT to ORT alone to see if adding rifaximin improves outcomes. Participants will: Take one rifaximin 200 mg tablet + ORT three times a day for 3 days or receive ORT alone Receive oral rehydration therapy according to the investigator's standard of care Attend up to 4 clinic visits over 5 days and receive 4 follow-up phone calls Provide blood samples on Day 1 and Day 3 for pharmacokinetic testing (rifaximin group only) Provide stool samples to identify bacterial pathogens Keep a diary of stool frequency and consistency to help determine when diarrhea resolves Be monitored for side effects, vital signs, and laboratory changes

Gender: All

Ages: 6 Years - 12 Years

Updated: 2026-08-13

7 states

Diarrhea
Gastroenteritis
Bacterial Infection
+1
RECRUITING

NCT06801067

A Study of SER-155 to Treat Diarrhea in People on Immunotherapy

The purpose of this study is to find out whether SER-155 may be a safe first treatment that causes few or mild side effects for people due to irEC.

Gender: All

Ages: 18 Years - Any

Updated: 2026-07-28

2 states

Diarrhea
Enterocolitis
RECRUITING

NCT07264985

Gut Microbiota and Diarrhea in Breast Cancer Patients Receiving Pyrotinib

Background: Pyrotinib is an effective targeted drug for HER2-positive breast cancer, but it very frequently causes diarrhea, which can be severe enough to disrupt treatment and reduce patients' quality of life. The reason why some patients develop diarrhea while others do not is not well understood. Recent research suggests that the community of bacteria in the gut (gut microbiota) may play a key role in this side effect. What is the purpose of this study? This is an observational study (Phase 1) that aims to understand the relationship between pyrotinib treatment, changes in gut bacteria, and the occurrence of diarrhea. The main goal is to compare the gut bacteria of patients who develop diarrhea while taking pyrotinib with those who do not. Researchers hope to identify specific bacteria that might protect against diarrhea, which could lead to new ways to prevent or treat this side effect in the future. What will happen in the study? Patients with HER2-positive breast cancer who are being treated with pyrotinib will be invited to participate. They will be divided into two groups: those who experience diarrhea and those who do not. Participants will provide stool samples at specific time points (e.g., 2 and 4 weeks after starting pyrotinib). They will also allow researchers to collect information from their medical records about their clinical condition and diarrhea symptoms. No experimental intervention will be administered in this phase of the study; all patients will receive standard medical care. Potential Benefits: Participants will not receive any direct benefit from this observational phase of the study. However, the information gathered may help scientists better understand pyrotinib-induced diarrhea and develop future strategies to help other breast cancer patients manage this side effect more effectively.

Gender: All

Ages: 18 Years - 75 Years

Updated: 2026-07-16

1 state

Breast Cancer
Drug-Related Side Effects
Diarrhea
ENROLLING BY INVITATION

NCT07300462

A Post-marketing Observational Study of Oral Cholera Vaccine

Chinese survey data indicate that the incidence rate of diarrhea in the general population ranges from 0.17 to 0.70 episodes per person-year, whereas among children under five years of age, the rate is significantly higher, ranging from 2.50 to 3.38 episodes per person-year. Over recent decades, rapid economic development has contributed substantially to the reduction of mortality associated with infectious diseases. However, emerging challenges-such as increasing antimicrobial resistance and heightened population mobility-have complicated efforts in infectious disease prevention and control. In a phase III clinical trial of the recombinant B subunit/bacterial whole-cell cholera vaccine (enteric-coated capsule), a statistically significant difference was observed in the overall incidence of diarrhea between the vaccinated group (12.9%) and the control group (26.7%) (P \< 0.01). Findings from similar vaccine studies conducted in Sweden have demonstrated cross-protection against diarrhea caused by enterotoxigenic Escherichia coli (ETEC) and other intestinal pathogens. Specifically, the vaccine conferred a 50% protection rate against Salmonella enterica infections, 82% against mixed infections involving ETEC and Salmonella, and 71% against mixed infections involving ETEC and other pathogens. Evidence from relevant studies suggests that the recombinant B subunit/bacterial whole-cell cholera vaccine may offer protective benefits against non-cholera infectious diarrhea. Nevertheless, there remains a paucity of real-world effectiveness data, particularly in pediatric populations who bear a disproportionately high burden of diarrheal disease.

Gender: All

Ages: 2 Years - 14 Years

Updated: 2026-07-10

5 states

Diarrhea